ClinicalTrials.gg
CompletedNCT07454863Updated May 14, 2026

A Mass Balance Study of DZD8586 in Healthy Male Participants (TAI-SHAN15)

A Phase 1 interventional study of DZD8586 in Lymphoma, Non-Hodgkin, sponsored by Dizal Pharmaceuticals. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by Dizal Pharmaceuticals · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 195 studies in Lymphoma, Non-Hodgkin with a site in China — 82 open to participants now, 109 under way, 14 of them phase 3. Lymphoma, Non-Hodgkin · China.

Enrollment
175th of 183
6 · median 58
Started
2026
with 11 others
Phase 1
79 of 195
33 open now
Registered
184th of 195
by date

Among the 195 studies in Lymphoma, Non-Hodgkin with a site in China, this one is the 175th largest by enrollment of the 183 interventional ones that give a count, is one of 12 that started in 2026, is one of 79 in phase 1, and was the 184th registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

82 of the 195 studies in Lymphoma, Non-Hodgkin with a site in China are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 195 studies in Lymphoma, Non-Hodgkin with a site in China, or all of them as a file.
02

Study summary

This phase I study is designed to evaluate absorption, metabolism and excretion (AME) profiles of [14C]-DZD8586, to determine the routes, rates of elimination, and mass balance of DZD8586 in healthy adult male participants. Participants will be administered a single oral dose of 50 mg of [14C]-DZD8586 (containing radioactive dose \~ 100 μCi) as a suspension.

03

Conditions studied

  • Lymphoma, Non-Hodgkin
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Each participant must meet all criteria below to be included in this study:

  1. Provision of signed and dated, written prior to any study-specific procedures.
  2. Healthy male volunteers aged 18 to 45 years (inclusive) with a (BMI) between 19 and 26 kg/m2(inclusive) and body weight > 50 kg.
  3. The results of physical examination, laboratory tests, chest X-ray (posteroanterior view), , and/or other auxiliary examinations (including abdominal ultrasound of the liver, gallbladder, pancreas, spleen, and kidneys; ophthalmologic examination; and digital rectal examination) are within normal results during the screening period or abnormal results with no clinical significance judged by the investigator.
  4. Male volunteers must be willing to use reliable methods of (condom) even if their partners are , surgically sterile, or using an effective hormonal method of contraception or intrauterine coil. In addition, volunteers must agree to continue to take similar contraceptive precautions through 12 months after the administration of DZD8586, and avoid procreative sex as well as sperm donation during this period.
  5. Be willing and able to comply with the study procedures, restrictions, and requirements.

Exclusion criteria

Exclusion Criteria:

Each participant who meets any of the criteria below will be excluded from this study:

  1. Abnormalities in vital signs assessment (including pulse, blood pressure, and tympanic temperature) that persist upon repeat measurement.
  2. History or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data.

    For gastrointestinal function, the patient who meets the criteria below should be excluded:

    • History or clinical manifestation of gastritis, gastrointestinal tract disorder, metabolic disorder, hepatic disorder, or other clinical condition
    • Nausea, vomiting, diarrhea, or malabsorption syndrome, or those with a history of severe vomiting or diarrhea within one week before the screening period.
    • Abnormal bowel movements (ie, on average production of less than 1 stool per day) or other gastrointestinal disorder that might affect the intake and absorption of the drug, as judged by the investigator.
    • Symptomatic hemorrhoids or perianal disease with regular/active rectal bleeding, irritable bowel syndrome, or inflammatory bowel disease during the screening period.
  3. History of other risk factors for TdP (such as heart failure, hypokalemia, and family history of long syndrome).
  4. During the screening period, the average resting corrected QTcF interval (QTC) on the is > 450 msec.
  5. Major surgery or severe trauma within 4 weeks before the screening, or scheduled surgery during the study period.
  6. History of hemorrhagic disease (including hemophilia, von Willey-Brandland disease, etc), stroke, or intracranial hemorrhage within 6 months prior to the screening.
  7. Blood donation (including blood products) or blood loss ≥ 500 mL within 2 months prior to the screening, or receiving blood products within 4 weeks prior to the screening.
  8. Participants with any or neoplastic disease history, except those who have undergone excisional surgery of non-melanoma skin cancer over 5 years prior to the screening.
  9. History of latent or active tuberculosis, or positive screening result.
  10. Bacterial infection (including) within 30 days prior to the screening is considered inappropriate for participation by the investigator.
  11. Any infection on screening tests for Treponema pallidum, Virus (HBsAg and HBcAb), Virus (HCV), or (HIV-Ag/Ab).
  12. History of severe allergy/ or ongoing allergy/hypersensitivity, or those who are known or suspected to be allergic to the product or any of its , as judged by the investigator.
  13. Has smoked an average of more than 5 cigarettes per day within the 3 months prior to screening, is a habitual user of nicotine-containing products, is unable to abstain from smoking/nicotine use during the trial period, or has a positive urine cotinine test.
  14. Has a known or suspected history of significant drug abuse (including licit or illicit drugs, alcohol, etc.) within 12 months prior to screening as judged by the investigator, a positive alcohol breath test result (>0 mg/100 mL) at screening, or a positive urine drug abuse screening test.
  15. Use of any prescribed medication within 4 weeks prior to the screening and refuse to restrict the use of prescription drugs Use or intention to use any prescription or over-the-counter medications (including but not limited to moderate to strong /5P inhibitor or inducers [including herbal products such as St. John's wort], any ADH and ALDH inhibitor/inducers, proton pump inhibitors, antacids, H2 receptor antagonists, and drugs that prolong QT/QTc interval, herbal products, natural or herbal supplements) within 4 weeks prior to the screening and through the end of the study, unless deems acceptable by the Investigator (or designee) and Sponsor.
  16. Participants who received live or in the 4 weeks prior to the screening (or related AEs haven't disappeared).
  17. Has participated in other clinical trials and received any investigational product or device within 3 months prior to the screening, plans to participate in another clinical trial during this study, or is not the actual personnel participating in the trial.
  18. Participants monitored for radiation exposure as part of their occupation.
  19. Radioactive exposure (≥2 times chest/abdominal CT scans, or ≥3 times other types of X-ray examinations) or those who have participated in radiopharmaceutical labelling tests within one year before the screening period.
  20. Participants who had been administered any amount of a [14C]-labelled compound within 12 months prior to the screening.
  21. History of vasovagal response to needles or blood, difficult venous access, or intolerance to venipuncture.
  22. Judgment by the investigator that the volunteer is not suitable to participate in the study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Carbon-14 labeled DZD8586

    Single oral administration of Carbon-14 labeled DZD8586 50 mg/100 μCi on empty stomach

    Drug: DZD8586

Interventions

  • Carbon-14 labeled DZD8586

06

What researchers measure

Primary outcomes

  1. Total amount and recovery of the radioactive dose in urine and feces: Ae, Cum Ae, fe and Cum fe

    Time frame: All excreted urine and feces samples at specified time points during 0-504 hours after dosing will be collected

  2. Metabolic profiling of relative abundance of [14C]-DZD8586 and metabolite identification of [14C]-DZD8586 in plasma, urine, and feces

    Time frame: Conduct testing within 1 month after all subjects collect plasma, urine, and fecal samples at all time points required by the protocol

Secondary outcomes

  1. Peak plasma concentration (Cmax) of DZD8586

    Time frame: up to 504 hours post dose

  2. Peak plasma concentration (Cmax) of DZ4581

    Time frame: up to 504 hours post dose

  3. Peak concentration (Cmax) of total radioactivity concentration equivalents in plasma and whole blood

    Time frame: Conduct testing within 1 month after all subjects collect whole blood and plasma samples at all time points defined by the protocol

  4. Time to Cmax (Tmax) of DZD8586

    Time frame: up to 504 hours post dose

  5. Time to Cmax (Tmax) of DZ4581

    Time frame: up to 504 hours post dose

  6. Time to Cmax (Tmax) of total radioactivity concentration equivalents in plasma and whole blood

    Time frame: Conduct testing within 1 month after all subjects collect whole blood and plasma samples at all time points defined by the protocol

  7. Elimination half-life (t1/2,λz) of DZD8586

    Time frame: up to 504 hours post dose

  8. Elimination half-life (t1/2,λz) of DZ4581

    Time frame: up to 504 hours post dose

  9. Elimination half-life (t1/2,λz) of total radioactivity concentration equivalents in plasma and whole blood

    Time frame: Conduct testing within 1 month after all subjects collect whole blood and plasma samples at all time points required by the protocol

  10. Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC0-t) of DZD8586

    Time frame: up to 504 hours post dose

  11. Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC0-t) of DZ4581

    Time frame: up to 504 hours post dose

  12. Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC0-t) of total radioactivity concentration equivalents in plasma and whole blood

    Time frame: Conduct testing within 1 month after all subjects collect whole blood and plasma samples at all time points required by the protocol

  13. Area under the concentration-time curve from time zero to infinity (AUC0-inf) of DZD8586

    Time frame: up to 504 hours post dose

  14. Area under the concentration-time curve from time zero to infinity (AUC0-inf) of DZ4581

    Time frame: up to 504 hours post dose

  15. Area under the concentration-time curve from time zero to infinity (AUC0-inf) of total radioactivity concentration equivalents in plasma and whole blood

    Time frame: Conduct testing within 1 month after all subjects collect whole blood and plasma samples at all time points required by the protocol

  16. Apparent oral clearance (CL/F) of DZD8586

    Time frame: up to 504 hours post dose

  17. Apparent volume of distribution (Vz/F) of DZD8586

    Time frame: up to 504 hours post dose

  18. PK parameters for renal clearance (CLR) for DZD8586 and DZ4581 in urine

    Time frame: up to 504 hours post dose

  19. Amount and percentage of DZD8586 recovered in urine

    Time frame: up to 504 hours post dose

  20. Plasma DZD8586-to-total plasma radioactivity ratio

    Time frame: Conduct testing within 1 month after all subjects collect plasma samples at all time points required by the protocol

  21. Whole blood to plasma total radioactivity ratio

    Time frame: Conduct testing within 1 month after all subjects collect whole blood and plasma samples at all time points required by the protocol

  22. Frequency, type and severity of adverse events/serious adverse events

    Time frame: Up to 3 weeks

  23. Pulse rate

    Time frame: Up to 3 weeks

  24. Blood pressure

    Time frame: Up to 3 weeks

  25. Heart rate

    Time frame: Up to 3 weeks

  26. RR, PR, QRS, and QT intervals

    Time frame: Up to 3 weeks

  27. Number of participants with abnormal laboratory tests results (including blood chemistry, hematology, coagulation function, and urinalysis)

    Time frame: Up to 3 weeks

  28. Number of participants with abnormal physical and ophthalmologic examinations findings

    Time frame: Up to 3 weeks

07

Study locations

1 site
  • Affiliated Hospital of Jiangnan University
    Wuxi, Jiangsu 214062, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2026 to primary completion in Mar 2026, 0 months.

Of 163 industry-sponsored phase 1 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 70. This study's 0 months is below that.

Counting every sponsor, half of 286 studies reached it within 55 months; a quarter within 38 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2026
First posted
Mar 6, 2026
StartActual
Mar 16, 2026
Primary completionActual
Mar 27, 2026
CompletionActual
Apr 6, 2026
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07454863
Responsible party
Sponsor
First posted
Mar 6, 2026
Start date
Mar 16, 2026
Primary completion
Mar 27, 2026
Completion
Apr 6, 2026
Last update
May 14, 2026

Study contacts

Yiqing Zhao
principal investigator · Affiliated Hospital of Jiangnan University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Birelentinib

Start the discussion